A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA
Authors:
- 18 February 2026
- journal article
- review article
- Published by Elsevier in The Lancet Neurology
- Vol. 25 (3) , 268-278
Abstract
No abstract availableKeywords
Funding Information
- Arizona Department of Health Services
- GHR Foundation
- Banner Alzheimer’s Foundation
This publication has 38 references indexed in Scilit:
- Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive FunctionJAMA, 2025
- Lecanemab Treatment in a Specialty Memory ClinicJAMA Neurology, 2025
- Alzheimer Disease as a Clinical-Biological Construct—An International Working Group RecommendationJAMA Neurology, 2024
- Prevalence of Lung Cancer Screening in the US, 2022JAMA Network Open, 2024
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- Disclosing Alzheimer Disease Biomarker Results to Research ParticipantsJAMA Neurology, 2022
- Projecting the long‐term societal value of a disease‐modifying treatment for Alzheimer's disease in the United StatesAlzheimer's & Dementia, 2022
- The Future Is P-Tau—Anticipating Direct-to-Consumer Alzheimer Disease Blood TestsJAMA Neurology, 2021
- Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative DisordersJAMA, 2020
- World‐Wide FINGERS Network: A global approach to risk reduction and prevention of dementiaAlzheimer's & Dementia, 2020